Life Science Foundation

Investment addresses the need for disease-modifying therapies targeting the root causes of fibrosis Funding will support the advancement of CCN family inhibitor TRX-44 into clinical trials for treatment of fibrotic conditions including idiopathic pulmonary fibrosis (IPF) Novo Holdings and HealthCap co-created Tribune in 2020 COPENHAGEN, Denmark, March 26, 2025 /PRNewswire/ -- Novo Holdings today announced its participation in a €23 million Series A round for Tribune Therapeutics ('Tribune'). The round was led by new investor LifeArc Ventures and joined by Novo Holdings, HealthCap, Innovestor's Life Science Fund and Inven2 as well as new Series A investors Industrifonden and Investinor. Tribune Therapeutics was co-founded in 2020 by the Seed Investments team of Novo Holdings and HealthCap Ventures to create broadly applicable disease-modifying therapies for fibrotic diseases by targeting downstream, tissue-agnostic gatekeepers of scar formation and tissue remodelling. Through a Pioneer Innovator Grant, the Novo Nordisk Foundation – whose assets Novo Holdings manages – partially funded scientific discoveries at the Oslo University Hospital by Professor Håvard Attramadal and Ole J. Kaasbøll that led to Tribune's formation. The Pioneer Innovator grant programme is designed to advance science-based discoveries in sustainability and health by funding experiments and activities that push ideas toward proof-of-concept and beyond, in line with Novo Nordisk Foundation's vision of improving people's health and the sustainability of society and the planet. Tribune's lead programme, TRX-44, is currently in development for the treatment of fibrotic conditions including idiopathic pulmonary fibrosis (IPF). TRX-44 prevents scar formation by mimicking the structure and function of CCN5. CCN5 is an endogenous protein that naturally blocks the pro-fibrotic effects of other CCN family members, including CTGF/CCN2 and WISP1/CCN4, on multiple cell types contributing to fibrotic pathology. João Ribas, PhD, Principal of Novo Holdings, said: "Tribune's scientific founders have discovered key insights into the mechanism of action of CCNs, leading to an elegant and powerful approach to harness the biology of CCNs to shut down a key pro-fibrotic pathway. The novel path being advanced by Tribune holds potential for meaningfully impacting the treatment of multiple devastating and often terminal fibrotic indications." Georg Vo Beiske, PharmD, Tribune Chief Executive Officer and HealthCap Venture Partner, said: "Tribune's foundational science has far-reaching therapeutic potential, and Novo Holdings has been a great partner in bringing the company to fruition through its early support and extended network. As we advance toward the clinic, having the backing of such a strong investor group increases our confidence in our innovative approach to treat fibrotic diseases." About Tribune Therapeutics Tribune Therapeutics is a biotechnology company advancing novel medicines to treat fibrosis, regardless of the cause, tissue or diagnosis. The company was founded on groundbreaking structural insights into the CCN family of proteins, key drivers of scar formation that have historically been difficult to comprehensively target. Tribune is advancing multiple programs, including CCN5 mimic TRX-44. For more information, visit or follow us on LinkedIn. About Novo Holdings A/S Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people's health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation. Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S (Novozymes A/S) and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seed, Venture, Growth, Asia, Planetary Health and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development. As of year-end 2023, Novo Holdings had total assets of EUR 149 billion. About the Novo Nordisk Foundation Established in Denmark in 1924, the Novo Nordisk Foundation is an enterprise foundation with philanthropic objectives. The vision of the Foundation is to improve people's health and the sustainability of society and the planet. The Foundation's mission is to progress research and innovation in the prevention and treatment of cardiometabolic and infectious diseases as well as to advance knowledge and solutions to support a green transformation of society. SOURCE Novo Holdings WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Lonza is expanding its manufacturing sites in Rewari, India, and Suzhou, China, for hard gelatin capsules, the CDMO said Thursday, despite the company flagging last week that it is looking to exit the capsule and health ingredients market. The new manufacturing lines will be online in the third quarter of 2025. BioCentriq is building a new 60,000-square-foot headquarters in Princeton, NJ, which will have cell therapy manufacturing, the CDMO said Tuesday. The factory also has potential for future clinical and commercial manufacturing expansions up to 30,000 square feet. The site will be fully operational in the second quarter of next year. Thermo Fisher Scientific is divesting its commercial samples business to Knipper Health for an undisclosed sum. Knipper will absorb Thermo Fisher’s Memphis, TN, facility as well as an undisclosed number of employees. The transaction will be completed by September 2025 and will expand Knipper’s cold chain footprint, according to a Wednesday press release. New York’s first cell and gene therapy manufacturing facility has opened at the Roswell Park Comprehensive Cancer Center in Buffalo, according to a Monday release. The factory cost $98 million to build, with $30 million from Empire State Development. Eli Lilly and EVA Pharma have won approval for their insulin glargine injection from the Egyptian Drug Authority, Lilly said Tuesday. The companies started their partnership in December 2022, with Lilly supplying APIs to EVA, who manufactures the insulin products locally. Bavarian Nordic is licensing its mpox vaccine to the Serum Institute of India under a new partnership, it announced Monday. Bavarian will allow SII to manufacture and distribute the MVA-BN vaccine in India. Valneva is also licensing its single-shot chikungunya vaccine to SII, who will manufacture and seek approval for the asset in India and other parts of Asia, according to a Thursday release. Samsung Biologics is investing , via its Life Science Fund, in the Flagship-founded company Generate:Biomedicines, according to a Wednesday release. Generate uses AI software to discover and design protein therapies. No financial details were disclosed. Celltrion has launched a new CDMO arm, dubbed Celltrion BioSolutions, the company said Tuesday. Theratechnologies has submitted a Prior Approval Supplement to the FDA outlining the changes it made to the manufacturing of its drug Egrifta, which is approved in the US to reduce belly fat in HIV and lipodystrophy patients. The FDA has four months to OK the manufacturing changes, the company said Wednesday. VaxSen has drawn support from the US International Development Finance Corporation, the African Development Bank, and the International Finance Corporation worth $45 million to improve local vaccine supply chains in Africa, according to a Tuesday release. Polyrizon has tapped the CDMO Eurofins, also called Amatsiaquitaine, to supply material for its PL-14 allergy blocker, which is entering a study next year, according to a Wednesday release. French pharma company Biocodex tapped the logistics firm Kinaxis to access its supply chain platform, according to a Monday release. BioVaxys has secured 48 kgs of lipids to start its antigen packaging platform, the company said Tuesday. The platform can package mRNA, proteins, peptides and small molecules. Moberg Pharma has secured a new manufacturer and supplier of an ingredient (terbinafine) for its nail fungus drug named MOB-015, according to a Wednesday release.

Q4'22 consolidated revenue of KRW 965.5 billion and Q4'22 operating profit of KRW 312.8 billion. FY'22 consolidated revenue of KRW 3.00 trillion and FY'22 operating profit of KRW 983.6 billion. Strong growth momentum expected to continue with active expansions in capacity, geography, and portfolio. INCHEON, South Korea, Jan. 27, 2023 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization, today announced strong financial results for the fourth quarter and record-high earnings for the fiscal year 2022. "Our steady financial performance in the fourth quarter was driven by solid business growth with strong operational excellence and full utilization across all plants, further accelerated by the full inclusion of Samsung Bioepis in 2022," said John Rim, CEO and President of Samsung Biologics. "Looking ahead in 2023, we expect the positive business momentum to continue, with the completion and full operation of Plant 4 and construction of our next facility at Bio Campus II. We will also seek to further expand our portfolio by investing in new modalities to diversify our service offerings, and as the world's leading CDMO, we will continue to provide quality-driven services and contribute to saving the lives of patients around the globe." FOURTH QUARTER & FISCAL YEAR 2022 RESULTS The company reported KRW 965.5 billion in consolidated revenue and KRW 312.8 billion in operating profit in the fourth quarter. For the 2022 full-year financial performance, the company posted a record-high consolidated revenue of KRW 3 trillion and KRW 983.6 billion in operating profit. [KRW billion] On a standalone basis, Samsung Biologics recorded a revenue of KRW 2.44 trillion in 2022, an increase of 55% compared to the fiscal year 2021. Operating profit increased to KRW 968.1 billion from KRW 536.5 billion in the previous year. Fourth quarter 2022 revenue was KRW 747.7 billion, an increase of 68% from KRW 444.3 billion reported in the same quarter in the previous year. Operating profit was KRW 308.5 billion, 140% higher year-over-year. Fourth quarter 2022 net profit reached KRW 314.1 billion, an increase of KRW 217.1 billion from the fourth quarter of the preceding year, benefiting from maximized operational efficiency and a favorable foreign exchange rate. FISCAL YEAR 2023 OUTLOOK In line with the company's three-dimensional growth strategy, Samsung Biologics will continue expansions in capacity, geography, and portfolio in 2023. At the 2023 J.P. Morgan Healthcare Conference in January, the company shared its plan for entering into new business areas - antibody-drug conjugates (ADCs) and cell and gene therapy (CGT) - aiming to become a global top-tier biopharmaceutical company by 2030. Samsung Biologics is planning to build an ADC manufacturing suite in Plant 4 to start production in the first quarter of 2024. The company will also commence construction activities at Bio Campus II on the land it has purchased for KRW 426 billion in 2022, while continuing to invest in promising biotech companies through the Life Science Fund created with Samsung C&T. Samsung Biologics will continue to expand geographically to solidify its foothold in the global market beyond its San Francisco R&D Center, and plans to open new sales offices in Boston and New Jersey, where major big pharma companies are located, to be utilized as key communication portals with global clients. The company has been successful in accelerating the overall construction schedule of Plant 4, which commenced partial operations in October last year, within just 23 months since its groundbreaking. Upon its full completion in mid-2023, Samsung Biologics is expected to hold a total capacity of 604KL, reaffirming its position as the world's largest CDMO. With the increasing importance of sustainability in the healthcare landscape, Samsung Biologics will also continue to engage in environment-conscious practices and global initiatives to mitigate the risks of climate change. In recognition of the company's efforts to transition to net zero, Samsung Biologics was recently awarded the Terra Carta Seal from the Sustainable Markets Initiative. For more details on performance and financials, please refer to the Earnings Release. About Samsung Biologics Co., Ltd. Samsung Biologics (KRX: 207940.KS) is a fully integrated CDMO offering state-of-the-art contract development and manufacturing services. With proven regulatory approvals, the largest capacity, and the fastest throughput, Samsung Biologics is an award-winning partner of choice and is uniquely able to support the development and manufacturing of biologics products at every stage of the process while meeting the evolving needs of biopharmaceutical companies worldwide. For more information, visit samsungbiologics.com. Samsung Biologics Contact Claire Kim Head of Marketing and Global Communications Samsung Biologics [email protected] SOURCE Samsung Biologics